Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Zacks.com on MSN
ANIP Stock Rises 7% in a Week: Here's What You Should Know
ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the ...
We came across a bullish thesis on Ocular Therapeutix, Inc. on TipRanks’ YouTube channel. In this article, we will summarize ...
Holistic Bio Spa introduces its Medicine 4.0 framework, redefining regenerative healthcare with systems-based, ethically ...
This roundup highlights recent FDA updates related to drug approvals and devices used by optometric eye care professionals.
Detailed price information for Garrett Motion Inc (GTX-Q) from The Globe and Mail including charting and trades.
Ocular Therapeutix stock jumped over 18% in premarket trading after rejecting Sanofi’s $16 per share buyout offer, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback